Euroopa Liit - eesti - EMA (European Medicines Agency)

roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - oftalmoloogilised vahendid - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).

Euroopa Liit - eesti - EMA (European Medicines Agency)

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmoloogilised vahendid - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Eesti - eesti - Ravimiamet

cesra arzneimittel gmbh & co. kg - estsiin - kaetud tablett - 30mg 40tk; 30mg 100tk

Eesti - eesti - Ravimiamet

g.l. pharma gmbh - estsitalopraam - õhukese polümeerikattega tablett - 10mg 7tk; 10mg 28tk; 10mg 30tk; 10mg 14tk; 10mg 49tk; 10mg 60tk; 10mg 56tk

Eesti - eesti - Ravimiamet

g.l. pharma gmbh - estsitalopraam - õhukese polümeerikattega tablett - 20mg 7tk; 20mg 20tk; 20mg 56tk; 20mg 50tk; 20mg 98tk; 20mg 15tk; 20mg 500tk; 20mg 14tk; 20mg 49tk; 20mg 28tk; 20mg 100tk; 20mg 90tk; 20mg 84tk

Eesti - eesti - Ravimiamet

g.l. pharma gmbh - estsitalopraam - õhukese polümeerikattega tablett - 15mg 100tk; 15mg 20tk; 15mg 10tk; 15mg 49tk; 15mg 28tk; 15mg 7tk; 15mg 50tk; 15mg 14tk; 15mg 84tk; 15mg 98tk; 15mg 500tk; 15mg 60tk; 15mg 56tk; 15mg 90tk; 15mg 15tk; 15mg 30tk

Eesti - eesti - Ravimiamet

g.l. pharma gmbh - estsitalopraam - õhukese polümeerikattega tablett - 5mg 60tk; 5mg 15tk; 5mg 10tk; 5mg 500tk; 5mg 30tk; 5mg 28tk; 5mg 84tk; 5mg 56tk; 5mg 14tk; 5mg 7tk; 5mg 98tk; 5mg 49tk; 5mg 90tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

bayer ag - aflibercept - wet macular degeneration; macular edema; diabetes complications - oftalmoloogilised vahendid - eylea on näidustatud täiskasvanute raviks:neovascular (märg) vanusega seotud makuladegeneratsiooni (amd);nägemispuudega tõttu macular turse teisejärguline võrkkesta veeni oklusioon (branch rvo-või kesk-rvo);nägemispuudega tõttu diabeediga macular turse (dme);nägemispuudega tõttu on lühinägelik choroidal neovascularisation (lühinägelik cnv).

Euroopa Liit - eesti - EMA (European Medicines Agency)

samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - oftalmoloogilised vahendid - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Euroopa Liit - eesti - EMA (European Medicines Agency)

viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - oftalmoloogilised vahendid - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5. 1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5. 1),visual impairment due to diabetic macular oedema (dme) (see section 5. 1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.